Thimmaiah (Tim) Chendrimada
Founder Able Sciences
Seminars
Tuesday 1st December 2026
Morning Workshop
9:30 am
Moving Beyond CD19 to Identify the Next-Generation of Clinically Viable Targets
With clinical momentum building around CD19-targeted approaches, developers are increasingly exploring novel targets that can address a broader range of indications and enhance safety profiles. Join this interactive workshop to explore emerging approaches for target discovery and the opportunities these targets can enable across autoimmune cell therapy development.
In this workshop, our leaders will be:
- Leveraging AI and computational approaches for identifying novel autoimmune targets
- Establishing preclinical models for validating target selection in autoimmune contexts
- Translating learnings from T-cell engagers and immunology drug development to inform cell therapy target discovery
Thursday 3rd December 2026
Evaluating RNA-Based In Vivo CAR-T Platforms Against Established Delivery Technologies
12:00 pm
- Comparing RNA and lentiviral delivery approaches to understand trade-offs in durability, safety, and clinical applicability, enabling informed platform selection
- Exploring delivery challenges for in vivo immune cell engineering, including assessing approaches to improve targeting and manufacturability for broader therapeutic use
- Leveraging early clinical insights on safety and efficacy endpoints to guide platform positioning and inform transition from oncology into autoimmune applications
